Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non-melanoma Skin Cancer: An Interrupted Time-Series Analysis Using Swiss Claims Data.
Tamino ZappalàJesper HallasCarola A HuberDaphne ReinauChristoph R MeierJulia SpoendlinPublished in: Pharmacoepidemiology and drug safety (2024)
Our results suggest that the DHPC by Swissmedic in 2018 accelerated a pre-existing decline in the use of hydrochlorothiazide in Switzerland.